Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Accuray Incorporated (ARAY)

Accuray Incorporated (ARAY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 238,587
  • Shares Outstanding, K 89,025
  • Annual Sales, $ 418,790 K
  • Annual Income, $ -16,430 K
  • 60-Month Beta 1.96
  • Price/Sales 0.57
  • Price/Cash Flow N/A
  • Price/Book 6.22

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -0.07
  • Number of Estimates 3
  • High Estimate -0.04
  • Low Estimate -0.08
  • Prior Year -0.05
  • Growth Rate Est. (year over year) -40.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.46 +13.41%
on 11/01/19
2.99 -6.69%
on 11/06/19
+0.16 (+6.08%)
since 10/14/19
3-Month
2.35 +18.72%
on 08/16/19
3.42 -18.42%
on 08/15/19
-0.56 (-16.72%)
since 08/14/19
52-Week
2.35 +18.72%
on 08/16/19
5.40 -48.33%
on 02/22/19
-1.80 (-39.22%)
since 11/14/18

Most Recent Stories

More News
Accuray Incorporated Reports Inducement Awards Under NASDAQ Listing Rules

Accuray Incorporated (NASDAQ: ARAY) today reported, as required by NASDAQ Stock Market Rules, equity inducement awards to Suzanne Winter, the company's new Senior Vice President, Chief Commercial Officer....

ARAY : 2.81 (+4.85%)
Accuray (ARAY) Q1 Wider Than Expected, FY20 View Retained

Accuray (ARAY) reiterates revenue and adjusted EBITDA view for fiscal 2020.

TMO : 300.84 (+0.27%)
ARAY : 2.81 (+4.85%)
RMD : 145.44 (+0.11%)
EW : 240.62 (-0.72%)
Accuray (ARAY) Reports Q1 Loss, Lags Revenue Estimates

Accuray (ARAY) delivered earnings and revenue surprises of -10.00% and -4.03%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

ARAY : 2.81 (+4.85%)
Accuray: Fiscal 1Q Earnings Snapshot

SUNNYVALE, Calif. (AP) _ Accuray Inc. (ARAY) on Tuesday reported a loss of $9.4 million in its fiscal first quarter.

ARAY : 2.81 (+4.85%)
Accuray Reports Fiscal 2020 First Quarter Financial Results

Accuray Incorporated (NASDAQ: ARAY) today reported its financial results for the first quarter of fiscal 2020 ended September 30, 2019.

ARAY : 2.81 (+4.85%)
First Asia-Pacific hospital treats patients with RayStation and Radixact

Accuray Incorporated (NASDAQ: ARAY) - Thailand's Lopburi Cancer Hospital, a center of excellence for cancer treatment, is the first in the Asia-Pacific region to clinically use the combination of RaySearch's...

ARAY : 2.81 (+4.85%)
Accuray Appoints Medtech Veteran Suzanne Winter as Chief Commercial Officer

Accuray Incorporated (Nasdaq: ARAY) announced today that Suzanne Winter has joined the company as Senior Vice President, Chief Commercial Officer effective October 21, 2019. Ms. Winter will have global...

MHMNF : 54.5000 (unch)
ARAY : 2.81 (+4.85%)
Accuray To Report Fiscal 2020 First Quarter Financial Results on October 29, 2019

Accuray Incorporated (NASDAQ: ARAY) will report results for its first quarter ended September 30, 2019 on Tuesday, October 29, 2019 after the market close. Management will host a conference call to review...

ARAY : 2.81 (+4.85%)
AngioDynamics Boosts VIT Product Portfolio With New Buyout

AngioDynamics (ANGO) is likely to see an expansion of its already existing VIT product portfolio with the buyout of Eximo Medical.

ABMD : 220.97 (+0.44%)
ANGO : 15.11 (+0.60%)
ARAY : 2.81 (+4.85%)
AVNS : 31.95 (-1.99%)
Luminex Gets FDA Nod for ARIES MRSA Assay, Boosts Platform

Luminex (LMNX) receives FDA clearance for the ARIES MRSA assay, which is likely to provide a boost to the company's ARIES platform.

ARAY : 2.81 (+4.85%)
ABMD : 220.97 (+0.44%)
ANGO : 15.11 (+0.60%)
LMNX : 19.81 (-0.55%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Sell with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

See More Share

Trade ARAY with:

Business Summary

ACCURAY INCORPORATED based in Sunnyvale, Calif., is a global leader in the field of radiosurgery dedicated to providing an improved quality of life and a non-surgical treatment option for those diagnosed with cancer. Accuray develops and markets the CyberKnife Robotic Radiosurgery System, which extends...

See More

Key Turning Points

2nd Resistance Point 2.77
1st Resistance Point 2.72
Last Price 2.81
1st Support Level 2.64
2nd Support Level 2.61

See More

52-Week High 5.40
Fibonacci 61.8% 4.23
Fibonacci 50% 3.88
Fibonacci 38.2% 3.52
Last Price 2.81
52-Week Low 2.35

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar